secwatch.observer — SEC 8-K summary
======================================

Issuer:     Transcode Therapeutics, Inc. (RNAZ)
CIK:        0001829635
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001104659-25-102361
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 3.03, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransCode amends preferred stock terms: caps conversion at 19.9% of Oct 8 common, removes delisting conversion right
--------------------------------------------------------------------------------

- Filed Amended and Restated Certificate of Designation for Series A and B Preferred on Oct 27, 2025.
- Caps aggregate conversion at 19.9% of common outstanding as of Oct 8, 2025, per Nasdaq listing rules.
- Removed holders' right to convert preferred into common upon delisting from Nasdaq.
- Amendment approved by majority of preferred holders and board; no new shares issued.
- Expects proxy statement for conversion approval and change-of-control proposals under Nasdaq rules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925102361/0001104659-25-102361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829635/000110465925102361/tm2529461d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-102361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer